1.	Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 040121, 04-C-0121, NCI-04-C-0121, NCI-6074, 6074, NCT00080821, NCT00077922
2.	Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 040142, 04-C-0142, NCI-04-C-0142, NCI-5943, NCT00085085, NCT00080535
3.	Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-06-C-0041, 7542, NCI-7542, NCI-P6702, NCT00295958
4.	Phase I Study of the Recombinant Immunotoxin LMB-2 in Patients With Tac-Expressing Leukemias and Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0064F, NCI-T95-0042N, T95-0042, NCT00002765
5.	Phase I Study of LMB-2 Immunotoxin in Pediatric Patients With CD25-Positive Relapsed or Refractory Leukemia or Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 6 months to 21 years Sponsor: NCI Protocol IDs: NCI-04-C-0168, NCI-5903, 5903, NCT00085150
6.	Pilot Study of Fludarabine Phosphate and Cyclophosphamide Followed By LMB-2 Immunotoxin in Patients With CD25-Positive Hodgkin's Lymphoma Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-06-C-0240, NCI-P6761, 7835, NCI-7835, NCT00389506